Sangamo Therapeutics - Earnings Call - Q3 2025

Executive Summary

• Revenue collapsed to $0.58M and diluted EPS was -$0.11; both were far below Wall Street consensus for revenue of $34.4M* and EPS of -$0.0418*; the miss was driven by the absence of collaboration revenue that boosted Q3 2024 results. Bold miss; consensus was based on S&P Global.
• Total GAAP operating expenses were $36.1M; non-GAAP operating expenses were $33.0M, down year-over-year on leaner staffing and lower licensing/patent costs, partially offset by BLA readiness for Fabry.
• Cash and cash equivalents were $29.6M; management expects runway into Q1 2026 after a $6M Pfizer license payment in October and ATM proceeds since quarter-end.
• FDA reaffirmed use of eGFR slope as endpoint for accelerated approval of ST-920 (Fabry); BLA submission targeted as early as Q1 2026; patient enrollment began for the STAND pain study, with first dosing expected in the coming months.
• Near-term stock catalysts: a Fabry commercialization partnership, initial dosing in STAND (pain), and continued regulatory clarity; all are explicitly prioritized by management.

What Went Well and What Went Wrong

What Went Well

• FDA meeting minutes reiterated agreement to use eGFR slope for accelerated approval, providing regulatory clarity ahead of the anticipated BLA filing. “The FDA reaffirmed its October 2024 agreement to use eGFR slope as an endpoint to support an accelerated approval pathway.”
• Clinical momentum: registrational STAAR data show positive mean annualized eGFR slopes at 52 weeks (1.965) and 104 weeks (1.747), supportive subgroup consistency, stable cardiac function, and durable α-Gal A expression up to 4.5 years.
• Operational progress in neurology: STAND pain study sites activated, enrollment underway; first patient dosing expected in the coming months; MHRA alignment on prion program CMC strategy.

Quote (CEO): “We continued to advance our clinical and pre-clinical pipeline this quarter… the announcement of detailed clinical data from our registrational STAAR study in Fabry disease, alongside our recent FDA meeting, marked important steps forward on the path to an anticipated regulatory submission.”

What Went Wrong

• Severe revenue decline versus prior year due to lack of collaboration revenue recognized in Q3 2024; Q3 2025 revenue fell to $0.58M vs $49.41M YoY.
• Return to net loss: Q3 net loss was -$34.93M vs net income of $10.67M in Q3 2024; diluted EPS fell to -$0.11 vs $0.04.
• Funding risk persists: filings and forward-looking disclosures emphasize need for substantial additional financing and going-concern risks if a Fabry commercialization agreement or other non-dilutive capital is not secured.

Transcript

Operator (participant)

Morning and welcome to Sangamo Therapeutics third quarter 2025 conference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilkie, Head of Investor Relations and Corporate Communications. Please go ahead.

Louise Wilkie (Head of Investor Relations and Corporate Communications)

Thank you.

Good morning everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo executive leadership team including Sandy Macrae, Chief Executive Officer, Nathalie Dubois-Stringfellow, Chief Development Officer, Greg Davis, Head of Research and Technology, and Prathyusha Duraibabu, Principal Financial Officer and Principal Accounting Officer. Slides from our corporate presentation can be found on our website, sangamo.com, and under the presentations page of the Investors and Media section. This call includes forward looking statements regarding Sangamo's current expectations.

These statements include, but are not limited to, statements relating to Sangamo's cash runway, Sangamo's plans to obtain additional capital and its ability to continue to operate as a going concern, the therapeutic and commercial potential and value of Sangamo's product candidates and technologies, Sangamo's ability to establish and maintain collaborations and strategic partnerships including the Fabry disease program, the anticipated plans and timelines of Sangamo and its collaborators for clinical trials, clinical data presentations and releases, regulatory submissions and regulatory approvals, upcoming catalysts and milestones, and other statements that are not historical fact. Actual results may differ materially from what we discussed today.

These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC, specifically in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 and subsequent filings and reports that Sangamo makes from time to time with the SEC. The forward looking statements stated today are made as of today and we undertake no duty to update such information except as required by law. Please note that all forward looking statements about our future plans and expectations are subject to our ability to secure adequate additional funding. Now I'll turn the call over to our CEO Sandy Macrae.

Sandy Macrae (CEO)

Thank you Louise and good morning to everyone joining the call today. This quarter we continue to advance our clinical and preclinical pipeline while managing our cash resources carefully. In September we presented promising detailed clinical data from a registrational STAAR study in Fabry disease demonstrating the potential for ST-920 as a one time durable treatment of the underlying pathology of Fabry disease for all types of Fabry disease patients. In October we were pleased to hold a meeting with the FDA to discuss the proposed efficacy and safety data package for a planned BLA submission, where in the meeting minutes the FDA reaffirmed its October 2024 agreement to use eGFR slope as an endpoint to support an accelerated approval pathway.

A particular highlight for me this quarter was attending the 15th annual Fabry Family Education Conference that brought together more than 200 Fabry patients, family members and volunteers to provide educational presentations and gather insights from patients, including those who have received ST-920. This is an event we are privileged to attend each year and it was humbling to spend time with this group of inspirational people of all age groups to learn more about their experiences with Fabry disease. I found it striking to hear firsthand the challenges these patients face, including their experiences with currently available treatments, yet also see the hope they have for treatment breakthroughs and their strong understanding of scientific advances and their unwavering support for one another.

I came away from the event more convinced than ever that patients are seeking an alternative to current standards of care alongside the peaks and troughs and associated symptoms that they can bring. Gene therapy, where the alpha-Gal A enzyme is expressed all day every day by the liver, is a fundamentally different treatment modality to what is available today. I was lucky to meet with some patients who received ST-920 as part of the STAAR study and their enthusiasm and excitement was overwhelming. They could not wait to tell me their experiences and one patient approached me to share how ST-920 has completely transformed their life. We have a responsibility to bring this medicine to the Fabry community in our prioritised neurology pipeline.

We are excited now to be recruiting and enrolling patients in the phase I/II STAND study in chronic neuropathic pain, our first ever neurology clinical study following the activation of the first two clinical sites. We also continue to advance our prion program ahead of the planned CTA submission next year. I would like to now hand directly over to Nathalie Dubois-Stringfellow, our Chief Development Officer, to provide additional details on these important programs. Prathyusha Duraibabu, our Principal Financial Officer, and I will then close the call by summarizing the key business and financial takeaways from this quarter.

Nathalie.

Nathalie Dubois-Stringfellow (Chief Development Officer)

Thank you, Sandy. First, I am pleased to share updates from our registrational phase I/II STAAR study evaluating isaralgagene civaparvovec or ST-920, our investigational gene therapy for the treatment of adults with Fabry disease. This quarter we presented encouraging detailed clinical data at the ICIEM 2025 conference in Kyoto, Japan. As we have shared previously, after a single dose of ST-920, a positive mean annualized estimated glomerular filtration rate or eGFR slope of almost 2 was observed at 52 weeks across all 32 patients dosed in this study. Furthermore, a positive mean annualized eGFR slope of 1.7 was observed in the 19 patients who have achieved 2 years of follow-up. Supportive mean annualized eGFR slopes were also observed across a variety of patient subgroups including gender, baseline ERT status, Fabry disease type, and baseline eGFR, showing consistency in effect across Fabry patients in the study.

For the first time, we share cardiac data including stable cardiac morphology, stable cardiac function, and stability in early marker of cardiac damage in the 32 patient with at least 52 weeks of follow up. These data are encouraging, particularly given that cardiac disease is a leading cause of death in Fabry disease patients. As we have outlined previously, a range of key secondary endpoints were also positive. We continue to see strong durability in the study up to four and a half years for the longest treated patient, and we are pleased to see an encouraging ongoing safety profile. Indeed, every day that passes we accumulate more data and as of today we are pleased to have three patients with at least four and a half years of follow up.

We believe that these data demonstrate the potential of ST-920 to provide meaningful and long lasting clinical benefit to a wide range of Fabry disease patients, even above current standards of care. In October we held a meeting with the FDA to discuss the proposed efficacy and safety data package ahead of the planned BLA submission. We are pleased that the FDA meeting minutes reiterated the October 2024 agreement that we may use eGFR slope as an endpoint to support an accelerated approval pathway, agree on the adequacy of the safety package to support the BLA submission, and provided valuable input on the clinical data package. We continue to prepare for our anticipated BLA submission under the accelerated approval pathway planned for as early as the first quarter of 2026.

Next, I'd like to focus on our prioritized neurology pipeline as this quarter we commenced patient enrollment and recruitment in the phase 1/2 STAND study evaluating ST-503, our investigational epigenetic regulator for patients with intractable pain due to small fiber neuropathy or SFN, following the activation of our first two clinical sites. SFN is a truly debilitating chronic neuropathic pain impacting more than 650,000 people across the U.S., Europe, and Japan. We are thrilled to be recruiting patients for our first ever neurology genomic medicine clinical study and expect to dose the first patient in the coming months. This quarter we are also pleased to present updated non-clinical data at the 9th International Congress on Neuropathic Pain in Berlin, Germany, which demonstrated the durability, potency, and selectivity of ST-503 in non-human primate alongside a favorable safety profile.

We believe the preclinical data for this program is compelling and we look forward to seeing how this translates into humans. We believe chronic pain is an area of strong market potential and we're particularly encouraged by the FDA's recent draft guidance on the development of non opioid analgesics for chronic pain, which seeks to accelerate safe and effective non opioid treatment and to reduce prescription related opioid misuse. We stand with the FDA in seeking safe, effective alternative pain relief options. As a reminder, this is a dose escalation study, which if positive could allow us to broaden into other potentially high value indications such as trigeminal neuralgia or oncology-related chronic pain. Nav1.7 is a well proven target with human genetic validation, which we believe provides pain franchise potential.

Finally, moving to ST-506, our epigenetic regulator for the treatment of prion disease to be delivered intravenously using our neurotropic STAC-BBB capsid. This quarter, we continue to advance clinical trial application, or CTA, enabling activities for the program ahead of our expected CTA submission as early as mid-2026. Following on from our productive meeting with the U.K.'s MHRA earlier this year, where we aligned on non-clinical safety and the clinical study design, this quarter we were pleased to hold another productive interaction with the MHRA, this time to align on the planned chemistry, manufacturing, and control, or CMC, strategy for the anticipated CTA submission.

In November we presented updated preclinical data at the Prion 2025 conference which demonstrated the potent combination of epigenetic regulator and capsid delivery technology for the treatment of prion disease, including a profound survival extension that was observed in an aggressive mouse model of prion disease alongside widespread brain delivery and significant prion reduction in nonhuman primates. Based on this compelling preclinical data, we are preparing for the CTA submission to test ST-506 in the clinic. Given the rapidly deadly nature of prion disease with no currently available treatment option, we anticipate demand for this planned study to be high with a short time frame to an expected data readout. Furthermore, this study would mark the first in human testing of our STAC-BBB capsid which if successful could unlock a broader neurology pipeline for advancement, including with potential partners.

We have deliberately chosen two lead neurology assets that use different delivery mechanisms and bring different development risk. We believe both of them independently offer significant potential value and provide additional expansion opportunity into related neurological indications. I would like now to hand over to Prathyusha Duraibabu, our Principal Financial Officer, to provide a financial update. Prathyusha.

Prathyusha Duraibabu (Principal Financial Officer)

Thank you, Nathalie. This quarter we continue to diligently prioritize and control spend while seeking ways to extend our cash runway as we continued business development discussions for a Fabry commercialization agreement. In October we received $6 million upon Pfizer's exercise of a buyout option from our 2008 license to use zinc finger modified cell lines. We also continue to engage in business development discussions across our Sangamo pipeline and platforms.

As of today, we believe our cash.

Cash equivalents, including the license fee received from Pfizer and proceeds from sales of common stock under our at the market offering program since September 30th, will be sufficient to fund our planned operations into the first quarter of 2026. Before handing back to Sandy, I'd like to emphasize that we remain resolutely focused on solving a long-term funding foundation to advance our promise pipeline. In the near term, we seek to bridge to that future through a balanced approach, actively pursuing non-dilutive business development opportunities while exploring appropriate capital options. I will now hand it back to Sandy for closing remarks.

Sandy.

Sandy Macrae (CEO)

Thank you Prathyusha. To close, I'm pleased with the pipeline advances. This quarter we held a meeting with the FDA where in the meeting minutes the FDA reiterated its October 2024 guidance that we may use eGFR slope as an endpoint to support an accelerated approval pathway. We presented detailed data from our registrational STAAR study in Fabry disease including a positive mean annualized eGFR slope at 52 weeks, and we're pleased to observe a wide range of other positive secondary endpoints. Taken together, we believe in the potential for ST-920 to provide meaningful multi-organ clinical benefits above current standards of care. The importance of this data has also been recognized externally with the acceptance this week of three platform presentations on our Fabry disease program at the upcoming World Symposium in 2026.

This quarter we began recruiting and enrolling patients in the phase I/II STAND study for chronic neuropathic pain. Following the activation of the first two clinical sites, we expect to dose the first patient in the coming months and we continue to advance our prion program towards an anticipated CTA submission as early as mid-2026. As Prathyusha outlined, solving our long term funding needs remains our number one priority. We continue to seek ways to raise additional capital alongside our focused effort to secure a Fabry commercialization partner. Before closing for questions, I want to reflect on the recent Nobel Prize in Physiology or Medicine awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their research on regulatory T cells or Tregs. At Sangamo, we proudly advanced the clinical development of Tregs, being the first known company to dose a patient with an engineered CAR-Treg.

In August of this year, we presented the clinical data from our TX200 study in kidney transplantation at the World Transplant Congress in San Francisco showing the clinical potential of CAR-Tregs to create a tolerogenic environment in the kidney alongside the ability to taper immunosuppression post TX200 dosing. These are encouraging results that we believe demonstrate the potential for an engineered CAR-Tregs in organ transplantation. We really want to say that we are thankful to everyone who has been involved in this first in human study. While we are pleased with these innovative scientific advances, we remain focused on our promising neurology pipeline and look forward to sharing further novel scientific developments with you all. Operator, please open the line for questions.

Operator (participant)

Thank you. At this time we will conduct a question and answer session. As a reminder to ask a question, you will need to press Star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press Star one again. Please stand by while we compile the Q and A roster. Our next question comes from Gena Wang from Barclays. The floor is yours.

Hang Hu (AVP of Biotech Equity Research)

Hi, thanks for taking my question. This is Hang Hu from Barclays on behalf of Gena Wang. Just a couple of questions on Fabry disease. Could you share with us what's the latest progress in your partnership deal negotiation? Also on the regulatory front, you shared your progress with FDA, but in light of recent news from Sangamo about uniQure, is any read through to your Fabry disease drug program?

Sandy Macrae (CEO)

I can't comment on the discussions uniQure had. What they're doing is important and difficult and we simply wish them well for patients with Huntington disease. What I can tell you about is our interactions with the agency and the written meeting minutes that we have that confirm our ability to use the eGFR data for one year to get accelerated approval. When we look at our data, the eGFR is very clear and compelling. It's the overall body of data, the safety of the product, the ease of use, the cardiac data, the SF-36, the kidney benefit. I believe that's what the agencies see and that's why they have remained steadfast in endorsing the use of eGFR at one year to allow us accelerated approval and to file this next year.

We have also had other interactions with the agency on CMC and manufacturing, and I know those sometimes are not quite as exciting as the clinical path forward. For genomic medicines and for AAV manufacturing, having the agency's agreement on how you will manufacture it and what the package that is going to be required for approval is, is essential. We are very confident on that progress. Just to kind of reflect on that, now that the agency has reaffirmed our accelerated approval pathway, this can only be helpful for our business development discussions.

Hang Hu (AVP of Biotech Equity Research)

Yeah, thanks. How about the first part of this question, like, could you share with us any progress, your status in partnership negotiation?

Sandy Macrae (CEO)

I'll just repeat what I said at the end there, that now that the FDA has reaffirmed both the CMC and the clinical pathway, it can only be helpful in those discussions.

Hang Hu (AVP of Biotech Equity Research)

Thanks a lot.

Operator (participant)

Thank you for your question. Our next question comes from Maury Raycroft from Jefferies. The floor is yours.

Maury Raycroft (Equity Research Analyst)

Hi, good morning and thanks for taking my questions. Just kind of following up on the last questions. Wondering if you're planning to have any additional meetings with FDA prior to a pre BLA meeting and do you need to have. Do you plan on having a pre BLA meeting and what additional clarification do you need from FDA at this point?

Sandy Macrae (CEO)

Nathalie, can you answer that?

Nathalie Dubois-Stringfellow (Chief Development Officer)

Yeah. As a result of the meeting we had with the FDA, we're really pleased with the clarity on the clinical and safety package required for the BLA submission. As Sandy mentioned, we also have clarity on the element for the CMC strategy and these interactions were recent. We are exploring at this point if there are further topics that require a pre-BLA meeting.

Sandy Macrae (CEO)

Nathalie, this is a bit of a regulatory fine point. One does not have to have a pre BLA meeting if you feel all the questions have been answered.

Nathalie Dubois-Stringfellow (Chief Development Officer)

Absolutely. Because we have RMAT, we've had this year many interactions either, you know, through meetings or correspondence where we had really good clarity on many of our questions. At this point we're really discussing internally if there is anything that remains to be discussed. There is the preliminary.

Sandy Macrae (CEO)

The RMAT process works well, doesn't it? Because it allows that ongoing interaction.

Nathalie Dubois-Stringfellow (Chief Development Officer)

Exactly, exactly. Yeah. We were very pleased this year on the responses from the FDA and, you know, they were always on time and we've had no delays in our discussions.

Maury Raycroft (Equity Research Analyst)

Got it.

That's helpful. I guess just to, for the BD partners, assuming that this is kind of a three way conversation where you're relaying the regulatory information to these BD partners, is there any additional clarity that you need on the regulatory front that the BD partners need in order to make a decision?

Sandy Macrae (CEO)

I don't believe there are any questions left to answer. We have clarity on the primary endpoint and the agency has seen our one year data. That was part of the reason we had that recent clinical meeting, because the last time we showed it to them there were 18 patients at one year and now there are 32 patients at one year and 19 patients at two years. The certainty of the eGFR slope remains, which is something that the partners, potential partners, would clearly want to know. The CMC and manufacturing route is clear and the manufacturing process is underway and locked and loaded.

Maury Raycroft (Equity Research Analyst)

Got it.

Okay.

Thanks for taking my questions.

Operator (participant)

Thank you for your question. Our next question comes from Wells Fargo. The floor is yours.

Hi, thanks for taking our question. This is Kwan Ang for Yanan. Our question is also around the Fabry program. Can you share with us, in your engagement with FDA, has the topic of Commissioner's national priority review voucher ever been mentioned, and do you think that could affect your BD discussions?

Thank you.

Sandy Macrae (CEO)

Nathalie, can you comment on that?

Nathalie Dubois-Stringfellow (Chief Development Officer)

Yes. No, we have not discussed specifically that, but we are looking into it.

Got it.

Thank you. Have you shared all the details regarding the FDA meeting minutes with your potential partners, and any color you can comment on their reactions?

Thank you.

Sandy Macrae (CEO)

You can imagine when we got the minutes, we were pleased to share them with our partners or to share the essence of them, and any partnership that moves ahead, the partners would definitely see the minutes as part of the process. They always get to see all of the regulatory correspondence as part of any business development deal.

Got it.

Thank you so much.

Operator (participant)

Thank you for your question. Our next question comes from Patrick Trucchio from H.C. Wainwright. The floor is yours.

Luis Santos (Senior Equity Research Associate)

Good morning and thank you for taking our call. This is Luis Santos for Patrick. First want to say it is great to see the progress and the extension of your runway is commendable and reflects your financial discipline and we appreciate that. I want to ask a couple of questions on 503 in neuropathic pain and regarding the STAND study and the dosing that you said is going to start in the coming months, are there any additional challenges that we should consider recruiting this patient population and looking ahead into the readout in about a year, what would be a clear win to move this program forward? I have a follow up.

Sandy Macrae (CEO)

Nathalie, can you comment about how we're doing with getting the study going?

Nathalie Dubois-Stringfellow (Chief Development Officer)

Sure.

We're pleased to have already two sites activated that are actually right now screening patient and looking at the population. We've also broadened the population to SFN, not just idiopathic small fiber neuropathy, which really allows a broader scope in terms of finding patients. We are very optimistic that we will be able to dose the first patient in the coming months. We're also very active in opening other sites. We are going to have up to 10 sites in the study. In terms of the success of the trial, of course this is a dose escalation to look at the safety and tolerability of the study. We're also looking at efficacy in terms of the pain reduction from baseline using the PI-NRS, which is the overall pain intensity numerical rating scale, which is broadly recognized and widely used as preferred scale for pain measurement.

We will be monitoring this in a blinded fashion throughout the dose escalation.

Sandy Macrae (CEO)

Nathalie, it's been interesting the number of patients that have spontaneously from other places written to us and tried to get into the trial. It's clear that there's a high unmet medical need here.

Nathalie Dubois-Stringfellow (Chief Development Officer)

Yeah, absolutely. People have reached out to Sangamo or have seen the site activated in the clinicaltrials.gov page and have been directly contacting sites to see if they could be eligible throughout the country.

Sandy Macrae (CEO)

Luis, to your other question about what does efficacy look like? This is the first ever clinical dosing of something like this and I think we will understand it with every patient that we dose. It's not a medicine that is for every patient with neuropathic pain because it's a once and done treatment that will change their pain sensation forever. Therefore we will understand the population better in the coming months as we dose these patients.

Luis Santos (Senior Equity Research Associate)

Yeah, sounds great. Thank you for that overview. Regarding your platform, can you discuss any ongoing partner interests in the STAC-BBB capsid? Any additional deals that could extend your runway? Also, with your MINT platform progressing.

Sandy Macrae (CEO)

We're delighted with the progress of the capsid and the part. Yes, we are always talking to new people about the capsid. What's also important is the people that are working with the capsid. Genentech, Astellas, Lilly are also pleased and our relationship and discussions with them are going well. Greg, how's MINT doing?

Gregory Davis (Head of Research and Technology)

MINT is doing well. We continue to advance that platform in ways where we have minimal spend. We are trying to de-risk that technology from a molecular standpoint for MINT design towards genomic targets. We are trying to use our money wisely in that to keep that moving forward. We continue to advance business development negotiations for potential MINT partnership and look forward to sharing more information on those when we are able to.

Sandy Macrae (CEO)

Yeah, the success of the integration with the MINT platform is increasing every time the team come and show me it, and it really is a fundamentally important piece of science that we hope to speak a bit more about once in the future and hopefully put in the hands of others and Sangamo to make medicines from.

Luis Santos (Senior Equity Research Associate)

Great.

Thank you.

Operator (participant)

Thank you for your question. This does conclude the question and answer session. I would now like to turn it back to Louise Wilkie for closing remarks. The floor is yours.

Louise Wilkie (Head of Investor Relations and Corporate Communications)

Thank you once again for joining us today and for your questions. As a reminder, you can access our presentation on the Investor Relations section of the Sangamo website. We look forward to keeping you updated on our future developments.

Operator (participant)

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.